vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,212,121 shares of the business’s stock in a transaction dated Tuesday, July 9th. The stock was bought at an average price of $1.65 per share, with a total value of $1,999,999.65. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
NASDAQ:VTVT opened at $1.43 on Friday. The company’s 50-day simple moving average is $1.51. vTv Therapeutics Inc has a twelve month low of $0.68 and a twelve month high of $6.09. The stock has a market cap of $71.68 million, a P/E ratio of -2.07 and a beta of -3.71.
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.92 million for the quarter. Sell-side analysts forecast that vTv Therapeutics Inc will post -0.59 EPS for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Northland Securities set a $8.00 price target on shares of vTv Therapeutics and gave the company a “buy” rating in a report on Friday, June 28th. ValuEngine downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. Finally, HC Wainwright set a $10.00 price target on shares of T2 Biosystems and gave the company a “buy” rating in a report on Friday, June 7th.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Recommended Story: How does a reverse stock split work?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.